BP responses to exercise are similar in treated–controlled, treated-uncontrolled, and untreated hypertensives but higher compared with normotensives.
In the LEADER trial, patients with severe hypoglycemia episodes had a higher risk of CV events and mortality compared with patients without severe hypoglycemia, independent of treatment group.
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension
Clinical updates in management of cardiovascular risk Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.
Several reproductive factors, including early menarche, a history of miscarriage or hysterectomy, earlier age at first birth, or an early menopause, were associated with an increased CV risk in later life.
Dabigatran therapy was associated with a lower risk of major vascular complications without an increase in major bleeding in patients with myocardial injury after non-cardiac surgery.
In a pooled analysis of databases of 6 different countries, the initiation of SGLT2i was associated with lower risks of CV outcomes, as compared with other glucose-lowering drugs.
Before publication later this year, a first look at the new 2018 ESC/ESH Guidelines of hypertension was presented. One of the key messages was the unchanged definition of hypertension of BP >140/90 mmHg.
CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.
In breast cancer patients treated with radiotherapy or chemotherapy, the heart-specific mortality was not increased compared with the general female population.
Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.